Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EVAX

DatePrice TargetRatingAnalyst
4/2/2024$8.00Neutral → Buy
Ladenburg Thalmann
2/12/2024$14.00Buy
H.C. Wainwright
More analyst ratings

$EVAX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

    COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

    New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EVX-01The trial remains on track for two-year clinical efficacy data readout in the second half of 2025COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. D

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to present at numerous upcoming conferences

    Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting at several investor and scientific conferences in March and throughout the second quarter of 2025. Evaxion will be providing company and scientific updates as well as engaging with different stakeholders at conferences in both the US and Europe. As such, conference participation is an important part of our strategy to identify potential partners and opportunities for both

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EVAX
SEC Filings

See more

$EVAX
Leadership Updates

Live Leadership Updates

See more
  • Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

    Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion Biotech Appoints Lars Holtug to the Board of Directors

    COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Financials

Live finance-specific insights

See more
  • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

    COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to announce business update and third quarter 2024 financial results on October 31

    COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.  Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.  To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receiv

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

    COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance v

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more